Clinical trials: ACT
Cancer
Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies
ACT-PFK-158 is a novel anti-cancer agent that inhibits glucose uptake in cancer cells. The primary objective of the study will be to determine the maximum tolerated dose (MTD) and to describe any dose limiting toxicity.
- Trial name
- NCT02044861
- Testing
- PFK-158
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Advanced Cancer Therapeutics
Ovarian Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
This observational study will collect data about safety in female patients with advanced ovarian epithelial cancer with measurable residual disease after surger y.
- Trial name
- NCT02151370
- Where
- El Salvador
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Colorectal Cancer
Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of colorectal…
- Trial name
- NCT03821948
- Where
- 40 sites in United States
- Volunteers
- 5,131 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Activated Clotting Time
Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population
Measuring Activated Clotting Time (ACT) using the i-STAT ACTpro cartridge on the i-STAT 1 analyzer compared to a comparator device.
- Trial name
- ACT (NCT07382076)
- Testing
- Blood draw
- Where
- 11 sites in United States
- Volunteers
- 500 people
- Sponsor
- Abbott Point of Care
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
- Conditions
- Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related
- Trial name
- NCT07116473
- Testing
- Acoramidis (AG10)
- Volunteers
- 250 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Internet-based Intervention, Web-based Intervention
Evaluating Treatment Continuation in Telehealth Patients Receiving an Automated Patient-Reported Outcome Tool
Engaging patients through integration of patient-reported outcome measures in routine clinical care can improve the patient experience and provide a systematic way to collect adverse event (AE) data.
- Conditions
- Internet-based Intervention, Web-based Intervention, Online Intervention, Erectile Dysfunction
- Trial name
- NCT05895539
- Testing
- An automated patient-reported outcome data collection and adverse event surveillance tool
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Ro
Metastatic Breast Cancer
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
- Trial name
- ACT-MBC (NCT05662345)
- Testing
- CellSearch Circulating Tumor Cells
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Menarini Silicon Biosystems, INC
Malaria
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
This is a pilot, double-blind, randomized, parallel-group, placebo-control, exploratory study to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride (5-ALA HCl) and sodium ferrous citrate (SFC) added on…
- Trial name
- NCT04020653
- Testing
- 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD, Sodium ferrous citrate (SFC) 472 mg QD, Artemisinin-based combination (ACT)
- Sponsor
- Neopharma Japan Co., Ltd.
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.
- Trial name
- NCT06821750
- Testing
- PF-07314470
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Locally Advanced Pancreatic Adenocarcinoma
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
- Trial name
- ENACT (NCT06850623)
- Testing
- Acoustic Cluster Therapy, Modified FOLFIRINOX
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- EXACT Therapeutics AS
Advanced Solid Tumor
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
- Trial name
- NCT06257680
- Testing
- ReT01 ACT
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Xunsheng Biomedical Research Co., Ltd.
Urinary Incontinence
Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are…
- Trial name
- ACT (NCT00113555)
- Testing
- ACT (Adjustable Continence Therapy)
- Where
- 7 sites in United States, Canada
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Uromedica
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study…
- Trial name
- NCT06686797
- Testing
- PF-08049820
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pancreatic Adenocarcinoma Non-resectable
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
This study is being done to find out if delivering gemcitabine using the ACT-IOP-003 device directly to the area where the tumor is in the pancreas is safe and tolerable.
- Trial name
- NCT07481383
- Testing
- ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Continuity Biosciences, LLC
Rheumatoid Arthritis
Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia
This multi-center, observational study will evaluate the treatment patterns in clinical practice, efficacy and safety of tocilizumab in participants with rheumatoid arthritis (RA) who have had an inadequate response (or were…
- Trial name
- NCT01683604
- Testing
- Observational study
- Where
- 7 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity
This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity…
- Trial name
- NCT07731139
- Testing
- PF-08642534
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Colorectal Cancer
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of…
- Trial name
- NCT03789162
- Where
- 45 sites in United States, Canada
- Volunteers
- 850 people
- Sponsor
- Exact Sciences Corporation
Influenza, COVID-19 (Coronavirus Disease 2019)
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older.
- Trial name
- NCT06821061
- Testing
- Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine
- Where
- 31 sites in United States
- Volunteers
- 2,650 people, healthy volunteers welcome
- Sponsor
- BioNTech SE